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Objectives. The purpose of this study was to determine the
relative value of single-photon emission computed tomographic
(SPECT) imaging at rest using technetium-99m methoxyisobutyl
isonitrile (technetium-99m sestamibi) with positron emission to-
mography for detection of viable myocardium .
Background. Recent studies comparing positron emission to-
mography and thallium-201 reinjection with rest technetium-99m
sestamibi imaging have suggested that the latter technique under-
estimates myocardial viability.
Methods. Twenty patients with a previous myocardial infarc-
tion underwent rest technetium-99m sestamibi imaging and
positron emission tomography using fluorine (F)
.18 deoxyglucose
and nitrogen (N)-13 ammonia . In each patient, circumferential
profile analysis was used to determine tecbnetium
.99m sestamibi,
F-1S deoxyglucose and N-13 ammonia activity (expressed as
percent of peak activity) in nine cardiac segments and in the
perfusion defect defined by the area having technetium-99m
sestamibi activity <60% . Technetium-99m sestamibi defects were
graded as moderate (50% to 59% of peak activity) and severe
(<50% of peak activity)
. Estimates of perfusion defect size were
compared between technetium-99m sestamibi and N-13 ammonia.
Positron emission tomography, using perfusion and meta-
bolic imaging, is currently considered the most accurate
noninvasive method for differentiating ischemic but viable
myocardium from infarcted tissue . Its high cost and limited
availability have led to studies comparing its role with that of
conventional imaging techniques for assessing myocardial
viability. Recent studies have shown that imaging with
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Results . Sixteen (53%) of 30 segments with moderate defects
and 16 (47%) of 34 segments with severe defects had X60% F-18
deoxyglecose activity considered indicative of viability . Fluorine-
10 deoxyglucose evidence of viability was still present in 50% of
segments with technetium-99m ses
	
i activity <40% . There was
no significant difference in the mean (t SD) technetium-99m
mibi activity in segments with viable (40 t 7%) and nonviable
segments (49 : 7%, p = 0 .84) . Of the 18 patients who had adequate
F-18 deoxyglucose studies, the area of the technetium-99m ibi
defect was viable in 5 (28%). In 16 patients (80%), perfusion defect
size dete by tecbnetitnn • ibi exceeded that men
.
sured by N-13 ammonia. The difference in defect size tween
technetium-99m sestambi and N-13 ammonia was significantly
greater in patients with viable (21 t 9%) versus nonviable segments
(7 t 9%, p = 0.007) .
Conclusions. Moderate and severe rest technetium-99m sesta-
mibi defects frequently have metabolic evidence of viability . .
Technetium- sestamibi SPECT yields larger perfusion defects
than does N-13 ammonia positron emission tomography when the
same threshold values are used .
(J Am Coll Cardiol 1994;23
:92-8)
thallium-201 and reinjection after 3-h delayed imaging can
improve the diagnostic accuracy of this agent for detection
of viable myocardium (1,2) . Technetium-99m methoxyisobu-
tyl isonitrile (technet_iurn .99in sestamibi) is a perfusion im-
aging agent that has been shown to have similar accuracy to
thallium-201 for the detection of coronary artery disease
(3,4)
. Less is known with regard to its value in the detection
of viable myocardium (5,6) . Reliable estimates of the extent
of salvaged myocardium can be obtained using rest
technetium-99m sestamibi imaging before and after throm-
bolytic therapy for acute myocardial infarction (7) . How-
ever, in more chronic coronary artery disease states the
accuracy of technetium-99m sestamibi for assessing the
presence and extent of viable myocardium has not been
defined. Several recent studies have reported that rest
technetium-99m sestamibi imaging underestimates the num-
ber of left ventricular segments that are identified as viable
by positron emission tomography or thallium-201 reinjection
(8-10). However, this has not been a universal finding, and
to date most of the studies have relied on qualitative image
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(9-12) . in this investigation, quantitative anal
techniques were applied to determine the value of rest
technetium-99m sestarnibi imaging for detection of viable
myocardium using positron emission tomography as the
reference standard .
Methods
Study patients Twenty patients with a documented myo-
cardial infarction were enrolled in this study . The mean age
was 61 ± 8 years (range 44 to 71); 18 patients were men .
Fifteen patients had electrocardiographic (ECO) Q waves .
Six patients had previous coronary artery bypass grafting,
and three others had previous coronary angioplasty . Coro-
nary angiography was not performed as part of the investi-
gative protocol ; however, it was performed before recruit-
ment in 12 patients and during the study period in I patient .
Rest technetium-99m sestamibi imaging was performed 5
days to 3 weeks after infarction in 7 patients, and >6 months
after infarction in the remaining 13. The mean interval
between technetium-99m sestamibi imaging and positron
emission tomography was 18 ± 15 days . No subject under-
went revascularization or had a change in clinical status or
medical therapy between the two imaging studies .
Rest technetium-99m sestayalbi imaging . Seventeen pa-
tients underwent rest technetium-99m sestamibi imaging as
part of a 1-day rest-stress protocol, and rest imaging alone
was performed in three subjects . After an overnight fast,
each patient was injected with 8 to 10 mCi of technetium-
99m sestamibi. One hour after injection, imaging was per-
formed using a rotating gamma camera (GE 400 AC)
equipped with a high resolution collimator. The spatial
resolution at 100 mm was 10 .2 mm full-width half-maximum .
The photopeak was set at 140 keV with a 200/e window .
Sixty-four images over a 181V arc were acquired in a 64 x
64-pixel matrix for 25 s each
Positron emission tom ographic imaging. Informed con-
sent was obtained from each patient before positron emis-
sion tomographic imaging. The images were acquired using a
whole-body tomograph (ECAT 931 ,'Siemens) with an in-
plane resolution of 8 .5 mm. A 2-min scout transmission scan
was used to ensure appropriate positioning of the detectors
over the heart . A 15-min transmission scan was then ac-
quired for subsequent attenuation correction of emission
data. Each patient then received an intravenous injection of
20 mCi of N-13 ammonia . Three minutes after injection,
static images were acquired for a 10-min period . After decay
of the N-13 ammonia dose, 10 mCi of F-18 deoxyglucose was
administered intravenously . Forty minutes later, static im-
ages were obtained for a 10- to 20-min period. In subjects
without diabetes mellitus, F-18 deoxyglucose injection was
conducted after an oral glucose load. Short-acting insulin
was administered in five subjects with hyperglycemia ac-
cording to a protocol established in our laboratory to
hance myocardial uptake of F-18 deoxyglucose .
The transaxial data were reconstructed in a 128 x 128-
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pixel matrix using a Fanning filter with a cutoff frequency of
0.3 cycles/pixel . The transaxial images were reoriented along
the major axis of the heart and resliced to yield horizontal,
vertical and short-axis images using a computer workstation
(Sun Microsystems, Inc .) .
Qualitative analysis . The location of the infarct territory
was identified by clinical history and ECG information .
Twelve patients had an inferior infarction ; four had an
anterior infarction ; and four had both an inferior and an
anterior infarction . In each patient, the severity of reduction
in technetium-99m sestarnibi uptake in the infarct territory
was scored using a four-point grading system (4 = absent or
severe reduction ; 3 = moderate reduction ; 2 = mild reduc-
tion; 1 = normal) by a nuclear medicine physician who was
unaware of the clinical and quantitative image data . The
positron emission tomographic studies were visually as-
sessed. Moderate or severe reduction in both N-13 ammonia
and F-18 deoxyglucose activity was defined as a matched
pattern . Reduction in N-13 ammonia activity with normal or
enhanced F-18 deoxyglucose activity was defined as flow-
metabolism mismatch .
Quantitative analysis of segmental tracer activity . A semi-
automated regional analysis program, developed at our
institution, was applied to the short-axis rest technetium-
99m sestamibi, N-13 ammonia and F-18 deoxyglucose im-
ages (13). For each image, 8 to 12 short-axis planes encom-
passing the heart from the apex to the mitral valve plane
were used for analysis . The endocardial and epicardial edges
of the myocardium for each plane were defined by ellipses
chosen by an operator . The posterior point of intersection of
the right and left ventricles was also defined, and a radius
was automatically drawn between the center of the ellipse
and this point . A circumferential profile was then generated
for each plane using ti . - radius as the starting point . The
program searches for the maximal average activity in a 3 x
3-pixel area in each of 60 sectors for every plane. These data
were then displayed in a polar coordinate map . This map was
divided into five segments (septal, anterior, lateral, inferior
and apical) . Excluding the apex, the remaining segments
were further subdivided into basal and distal planes, yielding
a total of nine segments . The regional data were expressed as
the mean percent of the peak myocardial activity in the polar
map.
For the purposes of this study, regional F-18 deoxYglu-
cose uptake ?6017b peak activity was defined as metabolic
evidence for tissue viability . Regions with partial reduction
in F-18 deoxyglucose uptake (>50% of activity of normal
reference regions) have preserved wall thickening and may
represent a mixture of viable and infarcted myocardium
(1,14). In this study, F-18 deoxyglucose uptake was 71 ±
11% in segments distant from the infarct
territory that had
normal perfusion at rest and no stress-induced defects .
Thus, the threshold value chosen for viability was within
I SD of normal .
The reduction in technetium-99m sestamibi activ
graded as moderate (50% to 59% of peak activity) and severe
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(<50% of peak activity) . Techneti m-99m sestamibi and
N-13 ammonia activity were compared in patients with
viable (F-18 deoxyglucose -60%) and nonviable (F-18 deoxy-
glucose <60%) infarction zone segments.
Analysis of tracer activity in the perfusion defect . Analysis
of tracer activity within an individual segment may overes-
timate tracer activity within an ischemically injured territory
if the perfusion defect subscribes only a portion of any given
segment. For this reason, tracer activity was determined
within each perfusion defect . The area of the perfusion
defect was defined on the technetium-99m sestamibi polar
maps for each patient by choosing a threshold value of 60%
of peak counts (7,15). The territory defined by values below
this threshold was copied onto each patient's N-13 ammonia
and F-18 deoxyglucose images to derive perfusion defect
values for each of these tracers .
Estimation of perfusion defect size . Finally, perfusion
defect size was compared between technetium-99m sesta-
mibi and N-13 ammonia . A threshold value <50%® of peak
activity was chosen to define the most severely hypoper-
fused area of the ischemically injured territory for both
technetium-99m sestamibi and N-13 ammonia . The area of
the perfusion defect was expressed as a percent of the total
area of the polar map.
Statistical analysis. The data are reported as mean value
t 1 SD. Comparisons of tracer activity were made with
unpaired t tests . A statistically significant p value was
defined as < 0 .05 .
Results
Coronary anglography. Twelve of the 13 patients who
had coronary angiography before or during the study period
had significant disease (A50% diameter stenosis) of at least
one epicardial coronary artery or bypass graft. Four patients
had three-vessel disease ; six had two-vessel involvement ;
and two had one-vessel disease. The remaining patient had
bypass grafts without signifir nt obstruction . Nine (75%) of
the 12 patients who had significant coronary artery disease
had at least one totally occluded vessel .
QuandUffin ` . Quantitative analysis of technetium-
99m sestamibi and N-13 ammonia activity was conducted in
all patients . Two patients had F-18 deoxyglucose studies of
limited quality that could not be analyzed. Both of these
patients had hyperglycemia at the time of positron emission
tomographic imaging. and administration of insulin failed to
improve image quality. In the remaining 18 subjects, four
segments were excluded from analysis because of displace-
ment from the field of view or technical factors that pre-
vented accurate quantitation . Five additional segments were
excluded in two patients who had enhanced uptake of
technetium-99m sestamibi activity in lateral segments that
resulted in falsely reduced technetium-99m sestamibi activ-
ity in noninfarct segments . A total of 153 segments were
included in the comparison of segmental technetium-99m
sestamibi, N-13 ammonia and F-18 deoxyglucose activity .
FOG = F-IS deoxyglucose .
Segment analysis. The reduction in etium-99m ses-
tamibi activity within the infarction territory was qualita-
tively graded as severe in 15 patients and moderate in 5 .
Visual analysis revealed flow-metabolism mismatch in 9 of
18 subjects who had adequate F-18 deoxyglucose studies .
Using gttan .atatlve criteria, 19 patients had at least one
segment with severe reduction in technetium-99m sestamibi
activity, and the remaining patient had a moderate perfusion
defect. There were 34 segments with technetium-99m sesta-
mibi activity <50%. The technetium-99m sestamibi activity
in these segments was compared with the values from
segments in normal subjects with rest technetium-99m ses-
tamibi scans to determine whether activity <50% of peak
activity identified segments with a significant reduction in
tracer uptake. Thirty-two (94%) of the 34 segments classified
as having a severe defect had a reduction in tracer activity
2 SD below normal values .
The results of F-18 deoxyglucose imaging and the sever-
ity of reduction in technetium-99m sestamibi uptake are
correlated in 153 segments in Table 1 . Severely reduced
technetium-99m sestamibi uptake did not exclude the pres-
ence of significant F-18 deoxyglucose uptake . Sixteen 147%)
of 34 segments with severely reduced technetium-99m ses-
tamibi activity had evidence of viability. These 16 segments
were distributed among 10 (56%) of 18 patients who had
adequate F-18 deoxyglucose studies . Five patients had one
viable segment ; four had two viable segments; acid one had
three viable segments . Flow-metabolism mismatch was ob-
served in 5 of the 10 patients who had viable segments with
technetium-99m sestamibi activity <50% . There were still
equal numbers of viable (9) and nonviable (9) segments with
technetium-99m sestamibi activity <40% . The lowest values
of technetium-99m sestamibi activity in viable and nonviable
segments were 29% and 26%, respectively . Thus, no lower
limit of technetium-99m sestamibi activity was found that
excluded significant F-18 deoxyglucose uptake .
The predictive value of technetium-99m sestamibi activ-
ity -60% of peak activity for segment viability was 80% . The
predictive value of activity <60% for nonviable segments
was 50%. The positive and negative predictive values using
a threshold of 50% of peak activity were 73% and 53%,
respectively .
The mean activity of F-18 deoxyglucose in viable seg-
ments (69 ± 7%) was within the 95% confidence limits of
F-18 deoxyglucose uptake in noninfarct segments with nor-
mal perfusion (71 ± 11%). All segments exhibiting flow-
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table I . Technetium-99m Sestamibi Defect Severity and F-18
deoxyglucose Activity in 153 Segments
Technetium-99m Sestamibi Activity
(7e of peak activity) FDG ?60/ FDG <e0r1c
I 18
50-59 E6 14
<50 16 19
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Table 2. Segment and Perfusion Defect
99m Sestamibi, N-13 Ammonia and F-18 Deoxyglucose
Technetium-99m Sestarmbi <50%
FDD XW%
	
FDG <60%
Values presented are mean Me t I SD
. FDG = F-18 demygRosco
1'C = techriplium,
metabolism mismatch had F-18 deoxyglucose activity
e60%. The mean value of technetium-99m sestamibi in
segments with a severe defect did not distinguish between
those segments with and without viability (Table 2) . How-
ever, the mean value of N-13 ammonia activity was signifi-
cantly higher in viable compared with nonviable segments
(Table 2) .
Analysis of perfusion defect tracer activity . The perfusion
defect had F-18 deoxyglucose evidence of viability in 5
(28%) of 18 patients (Fig . It The mean values of technetium-
99m sestamibi, N-13 ammonia and F-18 deoxyglucose activ-
ity in the perfusion defect are shown in Table 2 . In contrast
to the segmental values of technetium-99m sestamibi activ-
ity, tracer uptake was significantly higher in defects with
viable myocardium compared with those without viability .
Perfusion defect size . The estimates of defect size by the
two blood flow tracers are shown in Table 3 . In 16 patients
the size determined by technetium-99m sestamibi exceeded
that measured by N-13 ammonia (Fig . 1) . The b1-13 ammonia
defects were marginally larger than the technetium-99m
sestarnibi defects in the remaining patients . Larger N-13
ammonia defects were confined to patients with nonviable
segments and perfusion defects . The mean difference in
perfusion defect size was compared between patients with
viable and nonviable defects and between those with and
without viable segments . The disparity in defect size was not
significantly different in those with and without viability in
the area of the perfusion defect (20 ± 9% vs . 13 ± 12%,
Figure 1. Technetium-99m sestamibi (Sesta-
mibi), nitrogen (N)-13 ammonia (Ammonia)
and F-18 deoxyglucose (FDG) polar maps in
a 56-year old patient with a severe sestamibi
defect (blue) with a mean activity of 43 ±
14% and F-18 deoxyglucose evidence of
viability (activity 70 ± 11%) . The infarction
area was measured at 36% of the left ventri-
cle by technetium-99m sestamibi and 27%
by N-13 ammonia.
P
Value
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Table 3. Perfusion Defect Size Determined by Tc-99m Sestamibi
and N-13 Ammonia
*p = 0.0022 . Ant = anterior ; Inf = inferior
; LV = left ventricle ; MI =
myocardial infarction: N = nitrogen
; Pt = patient ; Tc = technetium: U =
unknown.
respectively, p = 0 .31). However, the difference in defect
size was three times greater in patients with viable segments
(21 ± 9%) versus those without viable segments (7 ± 9%,
p = 0.0068) .
Discussion
Assessment of viability with technetium-99m sestamibi . In
the evaluation of patients with coronary artery disease, the
role of perfusion imaging has been expanded to include the
assessment of myocardial viability
. Single-photon emission
computed tomographic (SPELT) thallium-201 scintigraphy,
ect Size (% LV)
Pt
No .
Location Segment
allMI Viability
Perfusion
Defect
Viability
OAK N-13
Sestamibi Ammonia
Tc-99m
Sesaamibi-
Toll
Ammonia
I If Yes Yes 22 .5 1 .7 20 .8
2 Int Ant Yes Yes 36.0 26 .9 9 .1
3 Inf
Y4 s Yes 28 .3 4 .2 24 .1
4 W Yes Yes 14.4 1 .9 12 .5
5
Inf, Ant Yes Yes
72.5 41 .3 30 .9
6 It Ant Yes
No
26.1 18 .8 7 .3
7 hif Yes No 26.7 6 .8 19 .9
8
Inf
. Ant
Yes No 54.0 21 .5 32
.5
9 If Yes No 37.4 13 .8 23 .6
10 lot Yes No 32,6 3 .5 29 .1
H Ant No No 17 .1 9 .6 7 .5
12
Int No No 37 .6 20 .6 17 .0
13 Inf No No 23 .6 4 .0 19,6
14 Inf No No
18 .8 9 .0 9 .8
15 Ant U U
35,0 31 .8 4 .2
16 tuf No No 23 .3 8 .7 14.6
17 Ant No
No 7,6 12 .3 -4 .7
18 Ant No
N U 17'5 22 .1 -4 .6
19 Inf No N o 20.4 20.6 -0 .2
20 Inf U U
11 .5 12-0 -0 .5
Mean 28.2 14.6
± I SD
±15* ±11*
Segment
Tc-99M sestamibi 40 ± 7% 527%
0.843
N-13 ammonia 64 ± 9% 57 ± 8% 1018
FUMM 69 ± 7%
51 ± 8%
0 .0401
Perfusion defect
Tc-99m sestamibi 46 ± 3% 40 = 6% sms
N-13 ammonia 60 ± 3% 55 ± 7%
0 .16
F1 G 67 ± 5% 50 t 6%
0 .0001
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using imaging after reinjection, has demonstrated a sensitiv-
ity approaching that of positron emission tomography for
detection of viable myocardium (1,2) .
Technetium-99m sestamibi is a new perfusion tracer with
properties that suggest its potential for use in assessing
tissue viability, but this has yet to be established . Myocar-
dial cell viability is essential for technetium-99m sestamibi
uptake and retention (16,17) . Intracellular accumulation and
retention of technetium-99m sestamibi appear to be depen-
dent on the negative charge gradient generated by the
mitochondria (18). In the setting of acute myocardial infarc-
tion, technetium-99m sestamibi imaging before and after
successful reperfusion can be used to document the presence
and extent of myocardial salvage (7,19) . However, technetium-
99m sestamibi may be less useful for assessment of viability
when flow remains severely compromised, as in patients
with chronic coronary artery disease (6) . In this situation,
the close relation of flow and viability is uncoupled, so that
delivery and accumulation of the tracer may underestimate
viability .
Comparison of technetium-99m sestamibi and positron
emission tomographic metabolic imaging . The results of this
study demonstrate that technetium-99m sestamibi underes-
timates viability in this setting . The clinical significance of
this finding depends in part on the frequency of its occur-
rence. In a study of I I subjects, Soufer et al . (20) reported
underestimation of viability in only two segments . In our
investigation, metabolic evidence of viability was found in
-50% of segments with a moderate and severe reduction in
technetium-99m sestamibi uptake . The results of our study
are more in agreement with an investigation by Altehoefer et
al . (10) . who demonstrated that 52% of segments with 31% to
50% of peak technetium-99m sestamibi activity were viable .
These investigators utilized qualitative analysis of F-18
deoxyglucose scans for determination of myocardial viabil-
ity by identifying segments with matched and mismatched
patterns of technetium-99m sestamibi and F-18 deoxyglu-
cose activity . More recently, Vom Dahl et al . (21) reported
that 37% of segments with 40% to 49% of peak technetium-
99m sestamibi activity were viable when F-18 deoxyglucose
uptake a70% of the reference region was used as the
threshold for preserved viability .
Altehoefer et al . (10) and Yom Dahi et al . (21) found weak
correlations between the degree of technetium-99m sesta-
mibi activity and the presence of viability when segments
with activity <30% were separately categorized . We found
that ?50% of peak activity had a modest predictive value for
segment viability but that <50% of peak activity was poorly
predictive of norm;able myocardium. The studies of Altehoe-
fer et al . (10) and Vom Dahl et al. (21) also demonstrated that
reductions in technetium-99m sestamibi uptake
tni: range
30% to 49% of peak activity have
a poor predictive value for
nonviable segments .
All of the three most recent investigations have failed to
determine a lower limit of technetium-99m sestamibi activity
that reliably excluded myocardial viability . Technetium-99m
JACC Vol . 23, No . I
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sestamibi overestimates blood flow when perfusion is se-
verely reduced to levels resulting in myocardial injury
117,22) . Technetium-99m sestamibi activity in acutely in-
-~1rcted tissue may exceed 30% of the activity detected in
nonischemic regions (17) . Tissue viability may be preserved
with reductions in flow to 30% of normal rest values (23) .
Thus, it may not be possible to exclude the presence of
viable myocardium on the basis of the severity of reduction
in technetium-99m sestamibi activity .
Technetium-99m sestamibi imaging I h after injection
leads to underestimation of viability in a substantial propor-
tion of patients . Our study and that of Dilsizian et al . (8)
found that viability was underestimated in approximately
50% of those evaluated. However, in the majority of pa-
tients, viability was underestimated in only one or two
segments . Failure to detect small areas of viable myocar-
dium may have only a minor impact on the outcome of
patients with coronary artery disease . Revascularization in
patients who have limited amounts of viable myocardium
does not result in improvement in global systolic function or
exercise capacity, two of the most important prognostic
indicators in coronary artery disease (24,25) .
In our study, the analysis of F-18 deoxyglucose activity in
the area of the perfusion defect provided additional in-
formation on the extent of underestimation of viability by
technetium-99m sestamibi . The area encompassed by the
perfusion defect demonstrated viability in a minority of
patients, but in a few subjects (Table 3) the size of the defect
occupied substantially more myocardium than one segment .
Thus, in a few patients large areas of viable myocardium
may be missed .
Comparison of perfusion defect size . Perfusion defect size
was greater for technetium-99m sestamibi SPECT than for
N-l3 ammonia positron emission tomography when the
same threshold value for defining defect area was used for
both tracers . Previous investigators (26) have documented
the accuracy of N-13 ammonia for estimation of infarction
size. Overestimation of defect size was most pronounced in
those patients who had viable tissue. None of those with
comparatively larger N-13 ammonia defects had viable tis-
sue. These findings are consistent with those of Baudhuin
et al . (27), who demonstrated that the size and severity of
the perfusion abnormality were worse when assessed by
technetium-99m sestamibi . Our results indicate that the
degree of mismatch between perfusion defect size estimated
by the two blood flow tracers provides clues to the presence
or absence of viable myocardium .
Study limitations. The ultimate goal of methods used for
detection of myocardial viability is identification of myocar-
dium that will have improvement in contractile function with
revascularization. Our study and other investigations com-
paring positron emission tomographic and technetium-99m
sestamibi imaging have provided no information as to the
accuracy of this tracer for prediction of functional recovery
in revascularized myocardium . The results of these studies
and investigations demonstrating the high accuracy of
JACC Vol . 23, No_ I
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positron emission tomography for prediction of functional
recovery suggest that rest technetium-99m sestamibi may be
less useful for this purpose
. This speculation is supported by
a recent study indicating that the degree of technetium-99rn
sestarrtibi uptake is a poor indicator of functional recovery
after revascularization (28) .
In this and previous investigations, segments with de-
creased technetiumn-99m sestamibi activity were categorized
on the basis of tracer concentrations that were normalized to
the maximal values for each subject . This approach does not
take into account regional heterogeneity in tracer distribu-
tion that may particularly affect SPECT images lacking
attenuation correction . However, in our study nearly all
defects classified as severe by this approach had technetium-
99m sestamibi activity Z~2 SD below segmental values de-
rived from normal subjects . Additionally, there is modest
regional heterogeneity (13% to 19%) in myocardial glucose
utilization in normal subjects evaluated after glucose loading
(29,30) . Glucose utilization and F-18 deoxyglucose cent den-
trations are lowest in the septum. Selection of a single
threshold value for viability could lead to underestimation of
viability in septal segments . However, in our study all
"nonviable" septal segments had a reduction in F-18 deoxy-
glucose activity that was >19% below the threshold value
for viability . Additionally, all segments with flow-
metabolism mismatch had F-1S deoxyglucose activity
=60%.
The disparity in perfusion defect size may be partially
attributed to the differences in positron emission tomo-
graphic and SPECT methods
. Both the lack of attenuation
correction and the higher resolution of positron emission
tomography may have contributed to the observation of
larger technetium-99m sestamibi defects . Additionally, dif-
ferences in retention of the two perfusion tracers may
necessitate use of different thresholds for each .
Finally, a technetium-99m sestamibi protocol utilizing
imaging 1 h after tracer injection may not be optimal for
detection of viable myocardium . Technetium-99m sestamibi
is known to redistribute to a small degree, so that an
additional delay in imaging may have reduced the frequency
of viable myocardium in severe defects and the size of those
defects (31) .
Conclusions. The results of this and previous investiga-
tions indicate that SPECT imaging I h after injection of
technetium-99m sestamibi at rest has limited accuracy for
identification of myocardial viability on the basis of direct
comparison with metabolic positron emission tomographic
imaging . Thus, clinical decisions with regard to tissue via-
bility should not rely on assessment of the extent or severity
of technetium-99m sestamibi perfusion defects .
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